Close menu




December 8th, 2022 | 09:25 CET

Core One Labs, BioNxt Solutions, Moderna - Takeover battle in a billion-dollar market

  • Biotechnology
Photo credits: pixabay.com

The sharp correction of recent months hit the capital-intensive biotech sector particularly hard. Shares, mainly from the second tier, have, in some cases, had to absorb losses of more than three-quarters of their market value and are trading far below their cash levels. These distortions naturally attract the big players to acquire novel developments at bargain prices.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: CORE ONE LABS INC. | CA21872J2083 , MODERNA INC. DL-_0001 | US60770K1079 , BioNxt Solutions Inc. | CA0909741062

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Core One Labs - Relationship Status: It's complicated

    In love, engaged, married, or rather single? For once, the life sciences research and development company, which focuses on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments and the integration of new drug delivery technologies, is preparing for a possible marriage to a potential acquisition candidate.

    As such, Core Onle Labs is actively seeking investment and potential acquisition opportunities by strategic psychedelics or pharmaceutical companies. Once a suitable offer is received and an agreement is reached, the Company will inform shareholders and the market and provide all the necessary transaction details. According to management, an acquisition could represent a unique opportunity for Core One and its shareholders to enter new markets and product lines and for Core One to benefit from the strengths and synergies of a buyer.

    Despite a potential merger, the Canadians aim to turn the Company into one of the leading manufacturers of high-quality psychedelic medicines. As such, the first production run of the drug-grade psilocybin in a GMP-compliant facility is planned for January 2023 to test the Company's commercial production capabilities. Following a successful commercial production trial, the Company intends to advance toward full commercial production of its API-grade psilocybin and other psychedelic compounds. The market capitalization of Core One Labs is currently CAD 35.63 million, with the stock price losing approximately 88% since the beginning of the 2021 trading year.

    BioNxt Solutions - Strong growth in a broad portfolio

    At CAD 41.89 million, a market capitalization that is only marginally higher puts BioNxt Solutions, which recently traded as XPhyto, on the stock market scales. This should also put it in the sights of the big players. The big difference to Core One Labs is that the Canadians have a much broader and diversified portfolio. The accelerator, which has subsidiaries in Germany, focuses on developing the next generation of drug formulations, diagnostics and active pharmaceutical ingredients. Several projects are approaching commercialization.

    The Canadians reported notable successes in the fourth business area, the fast-growing market for psilocybin research. The global growth of the market for psychedelic drugs is gigantic. By 2029, this is expected to grow at an annual rate of 13.3% to reach a market volume of CAD 6.4 billion. BioNxt Solutions has filed a patent application for its collection of novel psychedelic compounds. The substance database can thus be targeted for the treatment of neuropsychiatric, neurodegenerative and neuroinflammatory disorders, including depression, tobacco, opiate and cocaine addiction, or alcoholism, among others. With 350 million people worldwide suffering from depression alone, one can only imagine the enormous potential of preparations successfully brought to market.

    The share, traded not only in Toronto but also in Frankfurt, is currently working on bottoming out. If the EUR 0.40 mark were to be exceeded, a striking buy signal would be formed, providing the stock with a short-term upside potential of 50% to the next resistance level at EUR 0.60. Currently, a non-brokered private placement of bonds is underway. The size was increased from CAD 2.6 million to now CAD 2.8 million.

    Pfizer and BioNTech vs Moderna

    Vaccine readiness is waning, and Corona is moving increasingly out of the Company's mind. Now a tangible dispute has erupted between the mRNA vaccine makers. Back in August, US pharmaceutical giant Moderna sued Mainz-based BioNTech for patent infringement of its technology, which Moderna said it had developed before the pandemic. A similar lawsuit against Pfizer and BioNTech was also filed in Germany. Now, however, came the return fire.

    The partners filed suit against their US adversary in a federal court in Boston. The Mainz-based company is seeking a counterclaim in the US to deny allegations of patent infringement and to establish that patents have not been infringed.

    The patent disputes have little impact on the positive development of the Moderna share price. Thus, after a breakout above the resistance at USD 188, the next hurdle would be found at around USD 250. RSI and MACD are close to further buy signals and should provide a tailwind.


    The corrections in the biotech sector make smaller companies with a full research pipeline attractive takeover targets. Core One Labs is already on a shopping spree, while the more broadly based BioNxt Solutions is on the verge of commercialization for several compounds. Moderna has established its bottom and should form a buy signal shortly.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on March 1st, 2024 | 17:05 CET

    Cardiol Therapeutics, Bayer, Coinbase - Which share will generate profits in the long term?

    • Biotechnology
    • Pharma
    • crypto

    The world of pharmaceuticals and life sciences is characterized by precisely documented studies in clinical research. If an active ingredient makes it to approval, there is the potential for a blockbuster worth billions. Cardiol Therapeutics has an active ingredient in the second phase of clinical research for the treatment of heart disease in people under 35 years of age. This active ingredient can also restore the quality of life of 26 million people worldwide who suffer from heart failure. Bayer continues to clean up the unresolved issues left behind by the former CEO. Did the weedkiller RoundUp® from the Monsanto deal possibly lead to improper treatment due to a lack of consumer protection information? The five-figure lawsuits still pending against Roundup are dampening the share's profit prospects. The situation is currently quite different in the cryptocurrency market. Bitcoin is outperforming everyone, and the Coinbase share is benefiting from it. Which investment generates profits in the long term?

    Read

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read

    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

    Read